Atopic dermatitis is a chronic inflammatory skin disease in which many ups and downs are repeated and long-term treatment is required. The current medicines for atopic dermatitis are effective in symptom relief, but also cause many adverse effects. For this reason, there is a demand for the developm...
Atopic dermatitis is a chronic inflammatory skin disease in which many ups and downs are repeated and long-term treatment is required. The current medicines for atopic dermatitis are effective in symptom relief, but also cause many adverse effects. For this reason, there is a demand for the development of a safe medicine that has excellent effects and can be applicable for a long time. In this study, I have explored natural products that have the potential as new therapeutic agents for atopic dermatitis and have been proven safe. Centella aisatica has been proven to have its various pharmacological actions including wound healing, but its anti-atopic dermatitic effect has not been investigated yet. Therefore, I aimed to elucidate the anti-atopic dematitis effect of titrated extract of Centella asiatica (TECA) and the action mechanism. And, I tried to improve the anti-dermatitic effect of TECA by adding the advantages of phytosome formulation. In addition, based on the anti-dermatitic effect of TECA, I investigated whether there was a synergistic anti-inflammatory effect when TECA was combined with Astaxanthin (AST), a potent antioxidant. In this study, I conducted the experiments, using both the phthalic anhydride-induced atopic dermatitis mouse model and the in vitro model of lipopolysaccharide-treated RAW 264.7 macrophage cells. First, I found that TECA alleviated the progression of atopic dermatitis. The histological analysis showed that TECA inhibited hyperkeratosis and infiltration of immune cells. TECA treatment inhibited the release of IL-1β, IL-6, TNF-α and IgE. TECA suppressed the iNOS and COX-2 expression, NO production, and NF-κB activity. Subsequently, I found that the application of phytosome formulation to TECA significantly inhibited the progression of atopic dermatitis even with a less amount of the active ingredient. TECA phytosomes inhibited hyperkeratosis and infiltration of immune cells, and they inhibited the release of TNF-α, IL-1β, IL-4, IL-13 and IgE. TECA phytosome treatment potently inhibited the iNOS and COX-2 expression, NO production, and NF-κB activity. In addition, I found that the combination of TECA and AST synergistically inhibited the atopic dermatitis progression. Treatment with TECA alone or AST alone inhibited hyperkeratosis, immune cell infiltration, mast cell infiltration, inflammatory cytokine release, iNOS and COX-2 expression, NO production, and NF-κB activity. However, TECA+AST combination treatment had a greater inhibitory effect even with the respective lower doses of TECA and AST. In this study, I found that TECA inhibits progression of atopic dermatitis through mechanism of NF-kB signaling suppression. Also, I found that the anti-inflammatory effects are greatly improved by applying phytosome formulation to TECA or by combining TECA with a potent antioxidant AST.
Atopic dermatitis is a chronic inflammatory skin disease in which many ups and downs are repeated and long-term treatment is required. The current medicines for atopic dermatitis are effective in symptom relief, but also cause many adverse effects. For this reason, there is a demand for the development of a safe medicine that has excellent effects and can be applicable for a long time. In this study, I have explored natural products that have the potential as new therapeutic agents for atopic dermatitis and have been proven safe. Centella aisatica has been proven to have its various pharmacological actions including wound healing, but its anti-atopic dermatitic effect has not been investigated yet. Therefore, I aimed to elucidate the anti-atopic dematitis effect of titrated extract of Centella asiatica (TECA) and the action mechanism. And, I tried to improve the anti-dermatitic effect of TECA by adding the advantages of phytosome formulation. In addition, based on the anti-dermatitic effect of TECA, I investigated whether there was a synergistic anti-inflammatory effect when TECA was combined with Astaxanthin (AST), a potent antioxidant. In this study, I conducted the experiments, using both the phthalic anhydride-induced atopic dermatitis mouse model and the in vitro model of lipopolysaccharide-treated RAW 264.7 macrophage cells. First, I found that TECA alleviated the progression of atopic dermatitis. The histological analysis showed that TECA inhibited hyperkeratosis and infiltration of immune cells. TECA treatment inhibited the release of IL-1β, IL-6, TNF-α and IgE. TECA suppressed the iNOS and COX-2 expression, NO production, and NF-κB activity. Subsequently, I found that the application of phytosome formulation to TECA significantly inhibited the progression of atopic dermatitis even with a less amount of the active ingredient. TECA phytosomes inhibited hyperkeratosis and infiltration of immune cells, and they inhibited the release of TNF-α, IL-1β, IL-4, IL-13 and IgE. TECA phytosome treatment potently inhibited the iNOS and COX-2 expression, NO production, and NF-κB activity. In addition, I found that the combination of TECA and AST synergistically inhibited the atopic dermatitis progression. Treatment with TECA alone or AST alone inhibited hyperkeratosis, immune cell infiltration, mast cell infiltration, inflammatory cytokine release, iNOS and COX-2 expression, NO production, and NF-κB activity. However, TECA+AST combination treatment had a greater inhibitory effect even with the respective lower doses of TECA and AST. In this study, I found that TECA inhibits progression of atopic dermatitis through mechanism of NF-kB signaling suppression. Also, I found that the anti-inflammatory effects are greatly improved by applying phytosome formulation to TECA or by combining TECA with a potent antioxidant AST.
주제어
#Atopic dermatitis Centella asiatica Phytosome Astaxanthin NF-kB
※ AI-Helper는 부적절한 답변을 할 수 있습니다.